PERSPECTA

News from every angle

← Back to headlines

Analysts Adjust Price Targets for Dell and Climb Bio Following Recent Reports

Wall Street analysts have revised their stock price targets for Dell Technologies and Climb Bio following recent corporate earnings releases and Phase 1 clinical trial results. The adjustments reflect updated investor expectations based on new financial and medical data.

4 Sept, 00:07 — 4 Sept, 00:07
PostShare

Sources

Showing 1 of 2 sources
thestreet5h ago

Analyst resets Dell stock price target after earnings

Here’s what could be next for Dell stock.

By Silin Chen

Read full article →

Coverage Timeline

First report: investing-com · 3 Sept, 18:06Full coverage: 2 · 6hWindow: 6h
Left-leaningCenterRight-leaning
investing-com3 Sept, 18:06First to report

BTIG raises Climb Bio stock price target to $32 on phase 1 data

6h later
thestreet4 Sept, 00:07Latest update

Analyst resets Dell stock price target after earnings

Related Stories

Volkswagen Approves Major Restructuring Plan Involving 100,000 Job Cuts

13m ago

US Investigates Deadly Strike on Iranian Wedding Linked to American Munitions

30m ago

Oil Prices Surge Amid Escalating Tensions Between the United States and Iran

38m ago

DSS Inc. Launches Public Offering to Raise Capital

1h ago